Fred Njeleka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fred Njeleka has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Andreas H. Diacon
TASK Applied Science Clinical Research Center Cape Town South Africa
2 shared publications - Bariki Mtafya
National Institute for Medical Research‐Mbeya Medical Research Center Mbeya Tanzania
2 shared publications - Daniel Adon Mapamba
National Institute for Medical Research‐Mbeya Medical Research Center Mbeya Tanzania
2 shared publications - Elin M. Svensson
Department of Pharmacy Uppsala University Uppsala Sweden
2 shared publications - Francesco Paolo Casale
Institute of AI for Health, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany
2 shared publications - Julia Dreisbach
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital Munich Germany
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8)
Modeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials
Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution. Our objectives were to evaluate TB‐MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modeling could provide insight into underlying biological processes. We generated TB‐MBLA (LifeArc) data from sputum samples from all 78 patients from the PanACEA BTZ‐043 Phase Ib/IIa trial and derived a summary measure of the joint distribution of the three TB‐MBLA, colony forming units (CFU), and time‐to‐positivity (TTP) biomarkers as the first principal component derived from a probabilistic principal component analysis (pPCA). With TB‐MBLA marker and the principal component 1 (PC1) values, we reevaluated the original stage IIa dose–response and stages Ib/IIa pharmacokinetics—pharmacodynamics (PK‐PD) exposure‐response analyses, applying linear and non‐linear mixed models, respectively. For TB‐MBLA, we could not detect an exposure‐response effect in the PK‐PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced E max exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modeling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. In this study, we present novel EBA data for the first‐in‐class antimycobacterial compound BTZ‐043 and contextualize the value of emerging bacteriological markers within the EBA trial framework. Trial Registration: ClinicalTrials.gov identifier: NCT04044001
- 7 August 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (8)
Open AccessModeling Treatment Response in Tuberculosis Early Bactericidal Activity Trials
Culture‐based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non‐culture‐based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB‐MBLA), could represent a solution. Our objectives were to evaluate TB‐MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modeling could provide insight into underlying biological processes. We generated TB‐MBLA (LifeArc) data from sputum samples from all 78 patients from the PanACEA BTZ‐043 Phase Ib/IIa trial and derived a summary measure of the joint distribution of the three TB‐MBLA, colony forming units (CFU), and time‐to‐positivity (TTP) biomarkers as the first principal component derived from a probabilistic principal component analysis (pPCA). With TB‐MBLA marker and the principal component 1 (PC1) values, we reevaluated the original stage IIa dose–response and stages Ib/IIa pharmacokinetics—pharmacodynamics (PK‐PD) exposure‐response analyses, applying linear and non‐linear mixed models, respectively. For TB‐MBLA, we could not detect an exposure‐response effect in the PK‐PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced E max exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modeling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. In this study, we present novel EBA data for the first‐in‐class antimycobacterial compound BTZ‐043 and contextualize the value of emerging bacteriological markers within the EBA trial framework. Trial Registration: ClinicalTrials.gov identifier: NCT04044001
- Open Access
Modelling treatment response in tuberculosis early bactericidal activity trials
Culture-based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non-culture-based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB-MBLA), could represent a solution. Our objectives were to evaluate TB-MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modelling could provide insight into underlying biological processes and reduce data loss. We generated TB-MBLA (LifeArc (R) ) data from sputum samples from all 78 patients from the PanACEA BTZ-043 Phase Ib/IIa trial. In addition, we defined a joint biomarker as the first principal component derived from a probabilistic principal component analysis (pPCA) integrating TB-MBLA, colony forming units (CFU), and time-to-positivity (TTP) data. With TB-MBLA alone and the principal component 1 (PC1) marker we reevaluated the original stage IIa dose-response and stages Ib/IIa pharmacokinetics - pharmacodynamics (PK-PD) exposure-response analyses, applying linear and non-linear mixed models, respectively. For TB-MBLA, we could not detect an exposure-response effect in the PK-PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced Emax exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modelling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. STUDY HIGHLIGHTS: What is the current knowledge on the topic?: BTZ-043 is a first-in-class antimycobacterial compound with promising applications in drug-sensitive pulmonary tuberculosis. TB EBA trials are typically conducted using sputum culture assays for dose-exposure-response modelling, but the technical challenges of these assays limit their effectiveness. What question did this study address?: How does the novel RT-qPCR assay TB-MBLA perform as a dose-exposure response marker for novel antitubercular compound BTZ-043 and what are the effects of joint modelling approaches in EBA modelling tasks? What does this study add to our knowledge?: We did not observe a significant exposure response for BTZ-043 in TB-MBLA over the 14-day treatment window. Joint modelling with pPCA can overcome the issues of missing and contaminated data that are canonical of culture data from TB treatment monitoring cohorts. How might this change drug discovery, development, and/or therapeutics?: Designing EBA trials should consider the drug-bacterial subpopulation axis of the specific study drug to maximise efficiency. Latent variable modelling techniques can be an effective and efficient framework for modelling Mycobacterial tuberculosis load in EBA trials.
Open AccessModelling treatment response in tuberculosis early bactericidal activity trials
Culture-based monitoring of bacterial load is slow and susceptible to missing data, contributing to the length and cost of TB clinical trials. Non-culture-based alternatives, like the Tuberculosis Molecular Load Bacterial Assay (TB-MBLA), could represent a solution. Our objectives were to evaluate TB-MBLA as a biomarker in early bactericidal activity (EBA) studies and explore whether combining biomarkers with joint modelling could provide insight into underlying biological processes and reduce data loss. We generated TB-MBLA (LifeArc (R) ) data from sputum samples from all 78 patients from the PanACEA BTZ-043 Phase Ib/IIa trial. In addition, we defined a joint biomarker as the first principal component derived from a probabilistic principal component analysis (pPCA) integrating TB-MBLA, colony forming units (CFU), and time-to-positivity (TTP) data. With TB-MBLA alone and the principal component 1 (PC1) marker we reevaluated the original stage IIa dose-response and stages Ib/IIa pharmacokinetics - pharmacodynamics (PK-PD) exposure-response analyses, applying linear and non-linear mixed models, respectively. For TB-MBLA, we could not detect an exposure-response effect in the PK-PD analysis, in contrast with CFU and TTP. When combining biomarkers, we observed a significant but less pronounced Emax exposure–response between days 0–3 compared with CFU and TTP alone. We also successfully applied pPCA as a modelling framework and show evidence that combining CFU and TTP in a joint latent component can improve detection of treatment effects compared with either biomarker alone. STUDY HIGHLIGHTS: What is the current knowledge on the topic?: BTZ-043 is a first-in-class antimycobacterial compound with promising applications in drug-sensitive pulmonary tuberculosis. TB EBA trials are typically conducted using sputum culture assays for dose-exposure-response modelling, but the technical challenges of these assays limit their effectiveness. What question did this study address?: How does the novel RT-qPCR assay TB-MBLA perform as a dose-exposure response marker for novel antitubercular compound BTZ-043 and what are the effects of joint modelling approaches in EBA modelling tasks? What does this study add to our knowledge?: We did not observe a significant exposure response for BTZ-043 in TB-MBLA over the 14-day treatment window. Joint modelling with pPCA can overcome the issues of missing and contaminated data that are canonical of culture data from TB treatment monitoring cohorts. How might this change drug discovery, development, and/or therapeutics?: Designing EBA trials should consider the drug-bacterial subpopulation axis of the specific study drug to maximise efficiency. Latent variable modelling techniques can be an effective and efficient framework for modelling Mycobacterial tuberculosis load in EBA trials.